ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

CYTO Altamira Therapeutics Ltd

1.58
-0.06 (-3.66%)
2024年5月4日 - 終了
15分遅延
名称 銘柄コード 市場 種別
Altamira Therapeutics Ltd CYTO NASDAQ 普通株式
  前日比 前日比 % 現在値 時刻
-0.06 -3.66% 1.58 13:00:05
始値 安値 高値 終値 前日終値
1.62 1.60 1.66 1.64 1.64
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/5/0121:47GLOBEAltamira Therapeutics Announces Filing of Provisional Patent..
2024/4/2421:47GLOBEAltamira Therapeutics Announces Publication of Positive..
2024/4/1021:00GLOBEAltamira Therapeutics Provides Business Update, Reports Full..
2024/4/0421:45GLOBEAltamira Therapeutics to Host Full Year 2023 Financial..
2024/3/2521:47GLOBEAltamira Therapeutics Announces Collaboration with..
2024/2/0722:47GLOBEAltamira Therapeutics’ Peptide-Based Delivery Platform Shown..
2024/1/2422:47GLOBEAltamira Therapeutics Files Second Provisional Patent..
2024/1/2307:02EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
2024/1/2214:15EDGAR2Form EFFECT - Notice of Effectiveness
2024/1/2006:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/1/2006:40EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
2024/1/2006:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2024/1/0907:02EDGAR2Form F-3 - Registration statement by foreign private issuers
2024/1/0822:47GLOBEAltamira Therapeutics to Present at 3rd Annual mRNA-Based..
2023/12/2922:47GLOBEAltamira Therapeutics Regains Compliance with Nasdaq Minimum..
2023/12/1122:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/12/1122:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/12/1122:00GLOBEAltamira Therapeutics Provides Investor and Business Update
2023/12/0823:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/12/0602:54GLOBEAltamira Therapeutics to Host Investor & Business Update..
2023/11/3000:20GLOBEAltamira Therapeutics Regains Compliance with Nasdaq Minimum..
2023/11/2306:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/11/2122:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/11/1723:04GLOBEAltamira Therapeutics Announces Partial Spin-Off of Bentrio®..
2023/11/1022:47GLOBEAltamira Therapeutics Announces European Patent Office..
2023/11/0105:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/10/0422:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/9/1421:47GLOBEAltamira Therapeutics Reports Additional Significant..
2023/9/1220:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/9/1220:30GLOBEAltamira Therapeutics Provides Business Update and First..
2023/9/0621:47GLOBEAltamira Therapeutics to Host First Half 2023 Financial..
2023/8/2321:47GLOBEAltamira Therapeutics to Present at H.C. Wainwright 25th..
2023/8/2120:31EDGAR2Form 6-K/A - Report of foreign issuer [Rules 13a-16 and..
2023/7/2820:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/7/2622:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/7/2021:47GLOBEAltamira Therapeutics and Pharma Nordic Collaborate for..
2023/7/1721:47GLOBEAltamira Therapeutics Announces Publication of Positive..
2023/7/1121:32EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2023/7/0805:14EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
2023/7/0521:47GLOBEAltamira Therapeutics Announces Collaboration with Heqet..
2023/6/3019:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..

最近閲覧した銘柄

Delayed Upgrade Clock